Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pha-543613. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 13/20 | 1.00 |
| ▸ | HTR3A | P46098 | 7/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 1.00 |
| ▸ | HTR3B | O95264 | 4/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pha-543613 SCHEMBL1458583 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Pha-543613 SCHEMBL5917894 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Pha-543613 SCHEMBL19379545 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Pha-543613 SCHEMBL6007449 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5917857 | 0.94 | CHRNA7 (0.90) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL842378 | 0.94 | CHRNA7 (0.90) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL843227 | 0.94 | CHRNA7 (0.90) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL843228 | 0.94 | CHRNA7 (0.90) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6009103 | 0.91 | CHRNA7 (0.84) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5704712 | 0.91 | CHRNA7 (0.84) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102192-A1 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | UNIV CALIFORNIA (US) | 2023-03-30 | — | — | US | claimed |
| EP-1699488-A2 | THERAPEUTIC COMBINATION FOR COGNITION ENHANCEMENT AND PSYCHOTIC DISORDERS | Pfizer Products Incorporated (US) | 2006-09-13 | — | — | EP | claimed |
| US-7067515-B2 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PFIZER INC. (US) | 2006-06-27 | — | — | US | claimed |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | PFIZER INC | 2006-01-26 | — | — | US | claimed |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CORBETT JEFFREY W | 2005-11-03 | — | — | US | claimed |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | PFIZER INC. | 2005-09-29 | — | — | US | claimed |
| EP-1572300-A1 | COMBINATION FOR THE TREATMENT OF ADHD | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1572205-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1572700-A1 | CRYSTALLINE FUMARATE SALTS OF 1-AZABICYCLO[2.2.2]OCT SUBSTITUTED FURO[2,3-C]PYRIDINYL CARBOXAMIDE AND COMPOSITIONS AND PREPARATIONS THEREOF | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| US-20050165047-A1 | Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof | PFIZER INC | 2005-07-28 | — | — | US | claimed |
| WO-2005063296-A2 | THERAPEUTIC COMBINATION FOR COGNITION ENHANCEMENT AND PSYCHOTIC DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | PFIZER INC | 2005-05-19 | — | — | US | claimed |
| WO-2004052894-A1 | CRYSTALLINE FUMARATE SALTS OF 1-AZABICYCLO[2.2.2]OCT SUBSTITUTED FURO[2,3-C]PYRIDINYL CARBOXAMIDE AND COMPOSITIONS AND PREPARATIONS THEREOF | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| WO-2004052461-A1 | COMBINATION FOR THE TREATMENT OF ADHD | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| EP-1406901-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | claimed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | claimed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | claimed |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2024-08-01 | — | — | US | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CHRNA7, CHRNG, CHRNE | CHRNA7 1/4885HTR3A 497/4885HTR3E 673/4885 |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885HTR3A 426/4885HTR3E 837/4885 |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | CHRNA3, CHRNA7, CHRNA2 | CHRNA7 2/4885HTR3A 66/4885HTR3E 80/4885 |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | CHRNA7 594/4885HTR3A 971/4885HTR3E 1472/4885 |
| US-20230102192-A1 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | CHRNA7, CHRNA3, CHRNA6 | CHRNA7 1/4885HTR3A 282/4885HTR3E 262/4885 |
| US-20050165047-A1 | Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885HTR3A 344/4885HTR3E 1167/4885 |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | CHRNA7 4612/4885HTR3A 3702/4885HTR3E 3159/4885 |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | CHRNA7, CHRNA10, SLC18A3 | CHRNA7 1/4885HTR3A 32/4885HTR3E 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.